antihypertensive drugs
J&J Gives Up On $230M Blood Pressure Drug After Disappointing Trial Results
Anika Sharma
Johnson & Johnson (J&J) is stepping back from its $230 million investment in a blood pressure treatment, aprocitentan, and returning ...
